Financial Data and Key Metrics Changes - For Q2 FY 2026, total revenue was $96.3 million, down from $113.9 million in the same period of FY 2025, primarily due to reduced demand from a longstanding customer and the transition of an End-of-Life program [3][4] - The net loss for Q2 FY 2026 was $8.6 million or $0.79 per share, compared to a net loss of $4.9 million or $0.46 per share in Q2 FY 2025 [7] - Adjusted gross margin for Q2 FY 2026 was 7.9%, while gross margin was 0.6%, down from 6.8% in the same period of FY 2025 [5][6] Business Line Data and Key Metrics Changes - The company initiated a wind down of manufacturing operations at its China facility, which is expected to save approximately $1.2 million per quarter once completed [5] - The company is also reducing its workforce in Mexico, anticipating savings of approximately $1.5 million per quarter [5] Market Data and Key Metrics Changes - Inventory decreased by $12.3 million or 12% year-over-year, while accounts receivable days sales outstanding (DSOs) improved to 77 days from 99 days a year ago, indicating stronger collection on receivables [8] Company Strategy and Development Direction - The company is focusing on nearshoring and tariff mitigation strategies to reduce costs while maintaining operational flexibility [4] - Investments in U.S. and Vietnam facilities are aimed at enhancing production capabilities and meeting evolving customer demands [11][15] - The company expects approximately half of its manufacturing to occur in the U.S. and Vietnam by the end of FY 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing global economic uncertainties and volatile trade policies but expressed optimism about new program ramps and cost efficiency improvements [9][10] - The company is not providing forward-looking guidance for Q3 FY 2026 due to uncertainties in new product launches [10] Other Important Information - The company reported a total cash flow from operations of approximately $6.3 million for Q2 FY 2026, compared to $1.3 million in the same period of FY 2025 [8] - Capital expenditures for FY 2026 are expected to be around $8-$10 million, focusing on new production equipment and automation [9] Q&A Session Summary Question: Can you provide more details on the increased demand from existing customers? - Management indicated that the increased demand is primarily from two longstanding customers, with a significant revenue impact from product maturation and an End-of-Life program [22][23] Question: What is the size and timing of the new programs won? - The automotive program is expected to generate up to $5 million, while pest control and industrial equipment programs could generate $2-$5 million each, with manufacturing taking place in Mexico and the U.S. [24] Question: Can you elaborate on tariff mitigation strategies? - The company is focusing on offering production options in Vietnam and Mexico to mitigate tariffs, leveraging the USMCA agreement for cost advantages [25][26] Question: What are the expectations for gross margin and revenue growth? - Management anticipates achieving breakeven by the end of the fiscal year, with expectations for revenue growth and margin expansion driven by the consignment program [39][40] Question: What is the impact of the wind down of China operations on costs? - The $1.2 million savings from the wind down will impact both cost of goods sold and operating expenses, contributing to overall cost reductions [44][45]

Financial Data and Key Metrics Changes - For Q1 fiscal year 2026, total revenue was reported at $98.8 million, a decrease from $131.6 million in the same period of fiscal year 2025 [3][4] - Gross margin improved sequentially to 8.4% from 6.2% in the previous quarter, but decreased from 10.1% year-over-year [4][5] - The company reported a net loss of $2.3 million, or $0.21 per share, compared to net income of $1.1 million, or $0.10 per share, in the same period last year [6][8] - Adjusted net loss was $1.1 million, or $0.10 per share, compared to adjusted net income of $2.8 million, or $0.26 per share, for the same period of fiscal year 2025 [6] Business Line Data and Key Metrics Changes - The consigned materials program has begun to ramp, which is expected to lower reported revenue compared to traditional turnkey programs, while gross margin is projected to improve [4][5] - The company won new programs in medical technology and industrial equipment during the quarter, with the medical program valued at approximately $5 million and two industrial programs combined at around $6 million [20][14] Market Data and Key Metrics Changes - Demand from longstanding customers has reduced total revenues compared to last year's first quarter results, influenced by global tariff uncertainties and macroeconomic conditions [11][12] - The Vietnam facility has doubled its manufacturing capacity, now capable of supporting anticipated future medical device manufacturing [12][13] Company Strategy and Development Direction - The company is focused on expanding production capacity in the U.S. and Vietnam to mitigate tariff impacts and meet customer demand for rebalancing contract manufacturing [11][12] - Strategic initiatives include enhancing materials resource planning algorithms and aligning inventory with current revenue [7][8] - The company anticipates that by the end of fiscal 2026, approximately half of its manufacturing will occur in the U.S. and Vietnam [13] Management's Comments on Operating Environment and Future Outlook - Management noted that uncertainties surrounding global tariffs and the macroeconomic outlook continue to delay new program launches [11][12] - The company expects to see growth in U.S. and Vietnam production, with a strong pipeline of potential new business [10][18] - Management refrained from providing forward-looking guidance for Q2 fiscal year 2026 due to uncertainties in timing for new product ramps [10] Other Important Information - Total cash flow from operations for Q1 fiscal year 2026 was approximately $7.6 million, down from $9.9 million in the same period of fiscal year 2025 [9] - The company reduced total liabilities by $21.8 million, or 9%, from a year ago, while accounts receivable days sales outstanding (DSOs) improved to 81 days from 92 days [8][9] Q&A Session Summary Question: What was the size of the new programs won this quarter? - The medical program was roughly about $5 million, and the two industrial programs combined are around $6 million [20] Question: Will the medical production capabilities be in Vietnam? - The intent is to have production for medical devices in Vietnam later this fiscal year, as certification has been received [21][22] Question: What revenue was generated from the consigned program this quarter? - The consigned program generated just over $1 million in revenue during the first quarter, with expectations to exceed $20 million annually [26] Question: What factors will influence the success of the consigned program? - The success depends on the customer's supply chain capabilities and timely provision of components [27][30] Question: What is the current status of the utility product program? - The utility product program experienced a delay but is ramping nicely in the second quarter [34] Question: What is the situation regarding excess capacity in Mexico? - The company has excess capacity in Mexico but expects to fill it with increased activity in the latter half of the fiscal year [40][41] Question: How is the relationship with the bank lender? - The relationship with the bank is solid, with cash generation and debt reduction being positive indicators [94]